Background -Limited information is known about the baseline frequency of canine CD20 positive ( + ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published.
Introduction
Cutaneous epitheliotropic T-cell lymphoma (CETCL) is an uncommon neoplastic disorder of canine skin making up <1% of canine skin tumours. 1, 2 It occurs in three principal forms: mycosis fungoides (MF), pagetoid reticulosis (PR) and S ezary syndrome (SS), and may affect the epidermis, dermis and adnexal structures in addition to mucosal tissues and the subcutis. 2 The aetiology of the disease is not well understood, the prognosis is poor and few reliable prognostic indicators exist. 3 A review of 148 cases showed a median survival time of 264 days across all forms of CETCL; dogs with disease limited to haired skin and dogs with multiple lesions had shorter survival times. 4 Another published case study documented cluster of differentiation 3 (CD3) and CD20 co-expression in cutaneous epitheliotropic lymphoma in a dog for the first time and another study documented CD20
+ enteropathy-associated T-cell lymphoma in three dogs. 5, 6 CD20 co-expression also has been investigated as a potential prognostic indicator for human cases of CETCL.
7 CD20 is a predominantly Bcell marker expressed on B cells prior to differentiation into plasma cells. [5] [6] [7] [8] The goal of this retrospective study was to determine, in dogs with CETCL, the baseline frequency of CD20 co-expression compared with CD3, paired-box 5 (PAX5) and CD79a; to attempt to characterize its relation to survival time and utility as a prognostic indicator. Additionally, this study aimed to compare survival time and prognostic factors with those published previously.
Methods and materials
In order to identify cases for inclusion, the electronic medical records of the veterinary teaching hospital was queried with the search terms "epitheliotropic cutaneous," "mycosis fungoides" and "cutaneous lymphoma." A search from the veterinary diagnostic laboratory's records also was completed with similar search terms. Additionally, cases submitted to the veterinary diagnostic laboratory from July 2017 until March 2018 which received a histological diagnosis of CETCL were included.
Inclusion criteria for the study were a histopathological diagnosis consistent with any form of CETCL and access to formalin-fixed paraffin-embedded tissue for additional immunohistochemical (IHC) staining.
Original haematoxylin and eosin (H&E) stained slides and any available IHC slides were obtained. Slides from all cases were reviewed to confirm the original diagnosis. Additional immunohistochemical staining was performed as needed such that each case had H&E, CD3, CD20, CD79a and PAX5 stained slides available for assessment.
The immunohistochemical stains used included a rabbit polyclonal anti-canine-CD3 antibody (#CP215, dilution 1:150, Biocare Medical; Concord, CA, USA), a mouse polyclonal anti-canine-CD79a antibody (#V-CM067, dilution 1:60, Biocare Medical), a mouse polyclonal anticanine-PAX5 antibody (#CM207B, dilution 1:100, Biocare Medical) and a rabbit polyclonal anti-canine-CD20 antibody (#RB-9031-P, dilution 1:1,000, Thermo Scientific; Fremont, CA, USA). Staining was performed in a routine manner.
Immunohistochemical stains were graded using a modified 0-3 system based on Clinical Laboratory Standards Institute recommendations. 9 For the cytoplasmic stains: 0, absence of staining; 1, weak staining of <50% of a cell population; 2, weak staining of >50% or strong staining of <50% of a cell population; and 3, strong staining of >50% of a cell population. Grades of 2 or 3 were considered positive grades. For nuclear stains: 0, complete absence of staining; 1, 1-10% staining in a cell population; 2, 11-50% staining in a cell population; and 3, 51% or greater staining in a population. Diagnostic confirmation and grading was performed jointly by two investigators. CD79a staining and PAX5 staining were used as controls to differentiate B-cell infiltration from the CD20 + T lymphocytes. Both CD79a and PAX5 are pan B-cell markers and have been used previously in dogs and humans to differentiate neoplastic lymphocyte populations. [5] [6] [7] 10, 11 Medical records for all cases were procured from either referring veterinary hospitals or veterinary teaching hospital records. Records were reviewed by a single investigator and clinical data including date of birth, sex, breed, weight, approximate date for the start of lesions, lesion descriptions (number of lesions and site), date of sample submission, age at the time of biopsy, number of days to diagnosis, form of cutaneous epitheliotropic T-cell lymphoma (MF, PR, SS), therapies attempted, date of last known follow-up, status of dog at the time of follow-up (alive, deceased), manner of death if applicable (euthanasia, progression of disease, unrelated disease) and reason for euthanasia, if applicable. Approximations of dates were made as needed based on clinical history provided. No follow-up was available in a single case (#24). One case (#14) had lymphocytic leukaemia at the time of diagnosis and flow cytometry was performed on both blood and an aspirate of neoplastic cells from the skin.
The collected data were subjected to statistical analysis using IBM SPSS Statistics 24 software (Armonk, NY, USA), and live animals were excluded from survival time calculations.
Results
A total of 24 cases met the inclusion criteria. Of those, 17 were confirmed as deceased at the time of the study. The median age at the time of diagnosis was 11 years (6.3-15.3 years), with a median weight of 23.5 kg (2.8-49.3 kg). A majority of the cases (18 of 24) were spayed females with the remaining six of 24 being neutered males. A variety of breeds were represented including flat-coated retriever, boxer, Boston terrier, wheaten terrier, golden retriever, beagle, Labrador retriever, shih tzu, long-haired dachshund, bulldog, Bernese mountain dog, toy poodle, Australian shepherd dog, Yorkshire terrier and mixed breed canine. All breeds were represented by a single individual with the exception of beagles (2), shih tzu (2), Labrador retriever (3), boxer (3) and mixed breed canine (4) . Reported comorbidities included intraabdominal mast cell tumour, intraabdominal lymphoma, adenocarcinoma of the apocrine gland of the anal sac, hypothyroidism, rectal carcinoma, chronic kidney disease and an unspecified tick-borne disease, each reported once. Some individual cases had multiple comorbidities.
Five cases had a single lesion. Of those, three had a lesion encompassing both a cutaneous region and mucocutaneous region, one had a purely mucosal lesion and one had a purely cutaneous lesion. Nineteen cases had multiple lesions, 13 being exclusively cutaneous, four being cutaneous/mucocutaneous, and one each being either cutaneous/mucocutaneous/mucosal or mucosal/ mucocutaneous. Reported therapies included steroids only (11); steroids and another antineoplastic therapy which was not CCNU (three); CCNU only (two); both steroids and CCNU (one); steroids, CCNU and another antineoplastic therapy which was not CCNU (three); complete surgical excision (one); no therapy (two); and unknown (one). Histologically, 20 cases were classified as MF, three as PR and one as SS, which was confirmed via flow cytometry. All cases were graded 0 for CD79a and PAX5 in the neoplastic cell population. Varying results were obtained for CD3/CD20 cytoplasmic expression with 10 cases graded a 3/0 for CD3/CD20 (Figure 1 ), one was graded 3/1 for CD3/CD20, eight were graded 3/2 for CD3/CD20, four were graded 3/3 for CD3/CD20 ( Figure 2 ) and one was graded 2/3 for CD3/CD20. Overall prevalence of CD3 + /CD20 + co-expression was 54.2%. Staining characteristics are summarized in Table 1 . The median time to diagnosis from onset of signs was 64 days.
Seventeen cases were used for calculation of survival time statistics. Both the survival time from approximate onset of signs and survival time from diagnosis were assessed. The median survival time for all cases from the time of onset of signs was 189 days and median survival time from the time of diagnosis was 99 days. Cases with single lesions had a median survival time of 662 days from the onset of signs and 646 days from the diagnosis of disease. CD3 + /CD20 À cases had a median survival time of 152.5 days after the onset of signs and 117 days after diagnosis, whereas CD3 + /CD20 + cases had a median survival time of 222 days after the onset of signs, and 80.5 days after diagnosis. Individual case data are available in Table S1 . There was no correlation between IHC staining and body location or number of lesions.
The survival time was not normally distributed based on Shapiro-Wilk test for normality. No statistical significance was identified when performing an independent sample Wilcoxon-Mann-Whitney U-test evaluating the survival times from onset of clinical lesions (P = 0.54) or time of diagnosis (P = 0.61) compared to CD20 staining characteristic.
Discussion
Cutaneous epitheliotropic lymphoma is most commonly T cell in origin, but B-cell cutaneous lymphoma has been reported. 12 To account for this possibility and to ensure any positivity was truly T cell in origin, the pan B cell markers CD79a and PAX5 were used to differentiate the neoplastic T-cell population from a potential B-cell population. This technique has been utilized previously in human case reports. 10, 11 Additionally, in case #14, flow cytometry of both skin aspirates and peripheral blood showed a homogenous expansion of a population of T cells consistent with T-cell lymphoma. CD20 + CETCL has been reported in human medicine but is comparatively rare, with only 20 cases reported. 10, 11 Apart from the sole case report mentioned previously, 5 to the best of the authors' knowledge, this is the first report of the prevalence of CD20 staining in canine cutaneous epitheliotropic lymphoma in multiple cases. Over 50% of the cases in this retrospective review were CD20 + , indicating there may be a higher prevalence of CD20 + cutaneous epitheliotropic Tcell lymphoma than thought previously. Our findings for median survival times, irrespective of immunohistochemical staining characteristics, were similar to those reported previously. 4 The significance of CD20 positivity in cases of cutaneous epitheliotropic T-cell lymphoma requires further characterization. In the current study, although a difference in survival times was appreciated, statistical significance could not be established due to the data being highly asymmetrical and skewed, which is likely due to the small sample size. Based on the results of the present study CD20 should not be used to differentiate B-cell and T-cell epitheliotropic lymphoma. B-cell markers such as CD79a or PAX5 are recommended based on our study, as all cases were negative despite the CD20 findings. With more investigation in a controlled prospective study and a larger number of cases, it may have value as a prognostic indicator.
Identifying cases of CETCL with CD20 positivity also may have a therapeutic application. Passive immuno- therapy is a growing field in oncology and anti-canine CD20 monoclonal antibodies which bind to the extracellular domain have been produced. 13 Anti-canine CD20 monoclonal antibodies have been used in conjunction with CD47 blockade in a mouse xenograft model of canine Bcell lymphoma with positive results.
14 Some monoclonal therapeutics have undergone clinical trials and received USDA approval for the treatment of canine B-cell lymphoma. 15 It also may be possible to apply these passive immunotherapies in cases of CD20 + CETCL in canine patients. This would be a significant step in the management of this condition, which would only be possible with confirmation of the CD20 status of CETCL which is not done as a routine practice, to the best of the authors' knowledge.
The primary limitations of this study were the small number of cases and retrospective nature of the study. Additionally, highly variable follow-up, limited data and nonstandardized therapeutic protocols all limited the ability to assign significance to the findings. caracter ısticas de tinci on fueron evaluadas para su relaci on estad ıstica con el tiempo de supervivencia medio.
Resultados -el tiempo de supervivencia general promedio fue de 189 d ıas despu es del inicio de los signos cl ınicos y 99 d ıas despu es del diagn ostico definitivo; 54% de los casos presentaba tinci on CD20 +. No hubo una correlaci on estad ısticamente significativa entre las caracter ısticas de la tinci on y el tiempo medio de supervivencia desde el inicio de los signos (P = 0,54) o desde el diagn ostico (P = 0,61). Conclusiones y significado cl ınico -el linfoma epiteliotr opico cut aneo canino tiene mayor porcentaje de positividad para CD20 que lo documentado previamente. Esto indica que la tinci on de CD20 puede ser inadecuada para diferenciar el linfoma epiteliotr opico cut aneo de c elulas T y c elulas B. Esto tambi en puede tener implicaciones terap euticas con la llegada de terapias con anticuerpos monoclonales CD20 caninos. 
Resumo Contexto -H a poucos relatos na literatura sobre a frequência do linfoma epiteliotr opico de c elulas T CD20 positivo ( + ) em cães. Apenas um caso canino foi publicado. Objetivos -Caracterizar a frequência de casos caninos de linfoma epiteliotr opico de c elulas T positivos na colorac ßão CD20 + e avaliar o seu valor como um indicador de progn ostico. Animais -Foram avaliadas bi opsias cutâneas de 24 animais de propriet arios diagnosticados com linfoma epiteliotr opico cutâneo. M etodos e materiais -Realizou-se um estudo retrospectivo dos prontu arios de 2011 a 2018. Foram coletados os dados do hist orico cl ınico e as lâminas de exames histopatol ogicos e imunohistoqu ımicos pr evios de 24 cães. Estas lâminas foram coradas com corantes imunohistoqu ımicos adicionais de acordo com a necessidade para avaliar os casos de linfoma epiteliotr opico de c elulas T para as colorac ßões CD3, CD20, CD79a e PAX5. As caracter ısticas de colorac ßão foram relacionadas estatisticamente ao tempo m edio de sobrevivência do paciente. Resultados -O tempo m edio de sobrevivência foi de 189 dias ap os o surgimento dos sinais cl ınicos e de 99 dias ap os o diagn ostico definitivo; 54% dos casos foram positivos para o corante de CD20 + . Não houve correlac ßão estat ıstica significativa entre as caracter ısticas de colorac ßão e o tempo m edio de sobrevivência ap os o in ıcio dos sinais cl ınicos (P = 0.54) ou ap os o diagn ostico (P = 0.61). Conclusões e significância cl ınica -O linfoma epiteliotr opico cutâneo canino apresenta uma maior frequência de positividade para CD20 que o relatado anteriormente. Isto indica que o uso de corantes para CD20 pode ser inadequado para diferenciar linfomas epiteliotr opicos cutâneos de c elulas T e c elulas B.
